PT  - JOURNAL ARTICLE
AU  - Jhansi L. Leslie
AU  - Erin Weddle
AU  - Lauren K. Yum
AU  - Ye Lin
AU  - Matthew L. Jenior
AU  - Benjamin Lee
AU  - Jennie Z. Ma
AU  - Beth D. Kirkpatrick
AU  - Uma Nayak
AU  - James A. Platts-Mills
AU  - Herve F. Agaisse
AU  - Rashidul Haque
AU  - William A. Petri, Jr
TI  - Lewis Blood Group Antigens are Associated with Altered Susceptibility to Shigellosis
AID  - 10.1101/2020.09.09.20191478
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.09.20191478
4099  - http://medrxiv.org/content/early/2020/09/11/2020.09.09.20191478.short
4100  - http://medrxiv.org/content/early/2020/09/11/2020.09.09.20191478.full
AB  - In a cohort of infants, we found that lack of the Lewis histo-blood group antigen was associated with increased susceptibility to shigellosis. Broadly inhibiting fucosylation in epithelial cells in vitro decreased invasion by Shigella flexneri. These results support a role for fucosylated glycans in susceptibility to shigellosis.Competing Interest StatementDr. Ma reports grants from The Bill and Melinda Gates Foundation during the conduct of the study. Dr. Lee reports grants from Bill and Melinda Gates Foundation, during the conduct of the study. Dr. Agaisse has nothing to disclose. Dr. Kirkpatrick has nothing to disclose. Dr. Platts-Mills has nothing to disclose. Dr. Nayak reports grants from Bill and Melinda Gates Foundation, during the conduct of the study. Dr. Petri has nothing to disclose. Erin Weddle has nothing to disclose. Dr. Jenior has nothing to disclose. Dr. Leslie has nothing to disclose. Dr. Yum has nothing to disclose. Dr. Haque has nothing to disclose. Dr. Lin has nothing to disclose.Clinical TrialNCT01375647Funding StatementThis study was supported by funding from the Bill and Melinda Gates Foundation and R01AI43596 (WAP) as well as T32AI007496 (JLL).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:]. All families participating in the study were consented. PROVIDE was approved by the ethical review boards of the International Center for Diarrhoeal Disease Research, Bangladesh, The University of Virginia, and the University of Vermont.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNA